Which medication is part of a monthly injection regimen for treating neovascular AMD?

Ranibizumab is a medication that is commonly used as part of a monthly injection regimen for treating neovascular age-related macular degeneration (AMD). It is a monoclonal antibody that specifically binds to vascular endothelial growth factor (VEGF), which plays a crucial role in the formation of abnormal blood vessels (choroidal neovascularization) associated with neovascular AMD. By inhibiting VEGF, ranibizumab helps to reduce the progression of vision loss and can even improve visual acuity in patients suffering from this condition.

The treatment protocol typically involves monthly injections for the first several months, with potential adjustments in frequency based on the patient's response and disease activity. This regimen is designed to achieve adequate control of the neovascular process and stabilize or improve vision outcomes.

Other medications listed, such as ocriplasmin and fluocinolone, serve different purposes and are not used specifically for the injection treatment of neovascular AMD. Ocriplasmin is primarily used for vitreomacular traction, while fluocinolone is a corticosteroid used for inflammatory conditions. Chloroquine, an antimalarial drug, is not related to the treatment of AMD. Therefore, ranibizumab stands out as the correct choice for this particular regimen.